Precigen shares surge 24.48% after hours following FDA approval of Papzimeos and strong Q3 results.

Precigen surged 24.48% in after-hours trading following FDA approval of its immunotherapy candidate PAPZIMEOS and strong Q3 2025 financial results. The company reported $2.92 million in revenue, far exceeding expectations, and highlighted early adoption momentum for its new therapy. Analysts at H.C. Wainwright raised their price target to $9 from $8.50, while Citizens reiterated a $8.00 target, citing the therapy’s potential for rapid adoption and robust liquidity ($124 million in cash). The stock’s sharp rise aligns with positive analyst sentiment and the commercial launch progress of PAPZIMEOS, which is expected to generate long-term growth despite near-term profitability challenges.